Eiger Competitors

Delisted . USA . 
Stock . Eiger Biopharmaceuticals
EIGRDelisted Stock  USD 0.74  0.03  3.90%   
Eiger Biopharmaceuticals competes with Spero Therapeutics, Bolt Biotherapeutics, Coherus BioSciences, Cingulate, and Lyra Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Eiger Biopharmaceutica competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Eiger Biopharmaceutica to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Eiger Biopharmaceutica competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.740.740.74
Details
Intrinsic
Valuation
LowRealHigh
0.700.700.81
Details
Naive
Forecast
LowNextHigh
0.750.750.75
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.620.770.92
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Eiger Biopharmaceutica. Your research has to be compared to or analyzed against Eiger Biopharmaceutica's peers to derive any actionable benefits. When done correctly, Eiger Biopharmaceutica's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Eiger Biopharmaceuticals.

Eiger Biopharmaceutica Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Eiger Biopharmaceutica and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Eiger and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Eiger Biopharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
XFOR
+ 0.82
LYRA
LYRA
+ 0.81
SPRO
XFOR
+ 0.8
SPRO
CING
+ 0.78
CHRS
APLT
+ 0.76
GRCL
FNCH
+ 0.73
CHRS
  
High negative correlations   
APLT
- 0.79
FNCH
XFOR
- 0.78
GRCL
GRCL
- 0.74
CHRS
APLT
- 0.73
CHRS
FNCH
- 0.68
GRCL
APLT
- 0.67
CING

Risk-Adjusted Indicators

There is a big difference between Eiger Stock performing well and Eiger Biopharmaceutica Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Eiger Biopharmaceutica's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
SPRO  1.78 (0.31) 0.00 (0.58) 0.00 
 0.00 
 3.79 
(4.58)
 14.92 
BOLT  1.77 (0.12) 0.00 (0.52) 0.00 
 0.00 
 4.84 
(4.48)
 14.96 
CHRS  4.15 (0.10)(0.02) 0.00  4.66 
(5.96)
 8.96 
(6.94)
 35.06 
GRCL  5.71  1.29  0.18  1.35  6.35 
(6.70)
 16.34 
(6.25)
 52.11 
NLTX  2.25 (0.12) 0.00  0.38  0.00 
 0.00 
 4.05 
(3.53)
 27.84 
CING  5.11 (1.12) 0.00 (1.07) 0.00 
 0.00 
 9.27 
(10.28)
 38.00 
LYRA  4.12 (0.75) 0.00 (0.47) 0.00 
 0.00 
 8.00 
(10.00)
 41.07 
FNCH  4.29 (0.29) 0.00 (0.34) 0.00 
 0.00 
 6.33 
(8.10)
 64.67 
APLT  3.88  1.10  0.23  5.52  3.40 
(4.53)
 5.60 
(6.33)
 78.72 
XFOR  4.97 (0.74) 0.00 (0.36) 0.00 
 0.00 
 6.90 
(10.61)
 62.35 
All Fundamental Data

Eiger Biopharmaceutica Competitive Analysis

The better you understand Eiger Biopharmaceutica competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Eiger Biopharmaceutica's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Eiger Biopharmaceutica's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
EIGR SPRO BOLT CHRS GRCL NLTX CING LYRA FNCH APLT
 3.90 
 0.74 
Eiger
 1.74 
 1.13 
Spero
 5.00 
 0.63 
Bolt
 5.79 
 1.28 
Coherus
 6.07 
 4.02 
Gracell
 1.43 
 0.69 
Neoleukin
 7.23 
 4.36 
Cingulate
 5.26 
 0.20 
Lyra
 2.18 
 8.51 
Finch
 6.47 
 10.21 
Applied
Market Volatility
(90 Days Market Risk)
Very steady
Dangerous
Extremely Dangerous
Abnormally volatile
Very steady
Very steady
Very risky
Out of control
Very steady
Risky
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Quite High
Quite High
Dangerous
Dangerous
Very High
Quite High
Dangerous
Below Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Hold
Strong Buy
Not Available
Not Available
Buy
Buy
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Hold
Strong Sell
Strong Sell
Not Rated
Not Rated
Strong Sell
Strong Sell
Not Rated
Strong Sell
Current Ratio
7.22
3.65
9.73
3.17
8.01
12.78
10.94
12.4
7.28
1.49
Net Asset
38.83 M
182.39 M
159.78 M
629.6 M
1.66 B
115.95 M
3.49 M
142.6 M
71 M
54.83 M
Profit Margin
N/A
0.15
N/A
-0.0015
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(68.74 M)
25.77 M
(74.34 M)
(193.94 M)
(509.64 M)
(56.48 M)
(22.95 M)
(65.25 M)
(32.48 M)
(64.53 M)
Operating Margin
-5.28
-1.87
-14.93
-0.0902
N/A
N/A
N/A
-49.43
N/A
-243.8
Current Valuation
3.88 M
(10.06 M)
(11.51 M)
319.66 M
3.32 B
(35.02 M)
4.2 M
(3.32 M)
10.74 M
1.09 B
Price To Book
0.87
0.94
0.33
73.19
4.39
0.44
1.16
0.63
0.14
201.63
Retained Earnings
(512.16 M)
(391.07 M)
(364.29 M)
(1.58 B)
(1.63 B)
(451.06 M)
(92.94 M)
(311.36 M)
(350.39 M)
(468.59 M)
Current Asset
57.21 M
7.3 M
53.49 M
197.39 M
N/A
289 K
N/A
12.7 M
N/A
37.74 M
Beta
1.85
0.63
0.92
0.69
-0.34
1.1
-0.91
-0.036
0.46
2.02
Number Of Employees
56
46
100
235
314
7
13
88
1
37
Shares Outstanding
1.48 M
54.52 M
38.27 M
115.21 M
96.57 M
2.35 M
3.21 M
65.46 M
1.61 M
116.36 M
Cash Flow From Operations
(74.55 M)
(32.99 M)
(69.53 M)
(174.88 M)
(482.65 M)
(45.61 M)
(15.04 M)
(63.3 M)
(31.5 M)
(55.17 M)
Total Debt
41.2 M
5.54 M
20.22 M
480.84 M
182.98 M
12.07 M
3.14 M
26.88 M
30.13 M
777 K
Return On Equity
-2.26
0.26
-0.58
-16.57
-0.32
-0.38
-2.74
-1.86
-0.63
-4.73
Z Score
N/A
N/A
N/A
N/A
1.78
-5.73
N/A
N/A
N/A
N/A
Return On Asset
-0.52
0.1
-0.29
-0.14
-0.19
-0.19
-1.04
-0.42
-0.22
-0.76
Number Of Shares Shorted
29.81 K
625.19 K
65.99 K
31.51 M
1.19 M
26.4 K
89.24 K
2.04 M
19.2 K
12.14 M
Book Value Per Share
-1.08
2.02
2.96
-0.76
16.9
34.18
6.82
0.32
11.86
0.051
Current Liabilities
5.35 M
6.04 M
9.12 M
106.02 M
N/A
1.02 M
N/A
4.82 M
N/A
11.19 M
Total Asset
38.83 M
182.39 M
159.78 M
629.6 M
1.66 B
115.95 M
3.49 M
142.6 M
71 M
54.83 M
Debt To Equity
0.38
0.19
0.11
N/A
0.11
0.11
0.084
0.008
0.35
0.14
Short Ratio
3.72
2.08
0.54
12.34
0.87
1.7
0.42
1.21
0.19
7.7
Target Price
30.0
5.0
1.75
6.5
10.58
1.5
48.33
1.25
90.0
14.67
Shares Owned By Institutions
43.86
23.04
58.19
70.09
63.11
45.58
2.29
58.83
11.35
94.77
Market Capitalization
2.55 M
61.61 M
24.11 M
147.47 M
989.87 M
8.2 M
14.01 M
12.98 M
1.94 M
1.19 B
Price To Earning
-2.04
81.2
36.55
4.22
N/A
-4.6
N/A
N/A
N/A
-7.46
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
-0.03
N/A
1.61
-0.02
N/A
Price To Sales
0.17
0.52
2.16
0.48
732.21
N/A
N/A
8.82
30.46
54.68
Net Income
(74.96 M)
22.81 M
(69.2 M)
(237.89 M)
(496.98 M)
(57.56 M)
(23.53 K)
(62.68 M)
(74.75 M)
(119.76 M)
Earnings Per Share
-58.5
0.08
-1.71
-0.09
-0.97
-12.28
-43.22
-1.49
-6.59
-1.42
Shares Owned By Insiders
11.79
20.13
3.45
1.39
16.39
16.46
3.3
0.65
53.48
5.23
Revenue
15.77 M
96.73 M
7.88 M
257.24 M
N/A
N/A
N/A
1.56 M
107 K
9.99 M
Working Capital
(15.45 M)
94.06 M
85.25 M
143.86 M
1.28 B
88.07 M
856.85 K
85.22 M
21.76 M
(16.8 M)
Cash And Equivalents
141.79 M
45.4 M
176.34 M
275.48 M
1.71 B
116.46 M
8.2 M
120.67 M
104.67 M
67.72 M
Cash Per Share
3.22
1.29
4.68
3.54
25.28
2.73
0.73
3.79
2.19
1.41
Gross Profit
11.65 M
(42.11 M)
1.62 M
(58.4 M)
366 K
N/A
(9 M)
(34.23 M)
(57.03 M)
N/A
Day Typical Price
0.75
1.13
0.62
1.29
4.07
0.69
4.42
0.2
8.61
10.05
Accumulation Distribution
0.0769
0.0598
0.12
0.14
0.0888
0.0563
0.0672
0.05
0.033
0.0983
Market Facilitation Index
0.06
0.07
0.08
0.2
0.38
0.04
0.31
0.01
0.29
1.03
Daily Balance Of Power
(0.50)
(0.29)
0.375
0.35
(0.68)
(0.25)
(1.10)
1.0
(0.66)
0.6019
Period Momentum Indicator
(0.03)
(0.02)
0.03
0.07
(0.26)
(0.01)
(0.34)
0.01
(0.19)
0.62
Rate Of Daily Change
0.96
0.98
1.05
1.06
0.94
0.99
0.93
1.05
0.98
1.06
Day Median Price
0.75
1.14
0.61
1.29
4.09
0.69
4.46
0.2
8.66
9.97
Price Action Indicator
(0.03)
(0.01)
0.035
0.025
(0.20)
(0.01)
(0.26)
0.01
(0.24)
0.56
Relative Strength Index
44.27
39.49
49.91
64.11
52.59
38.93
45.24
42.12
40.95
63.57
Coefficient Of Variation
N/A
(997.05)
(3,036)
63692.81
584.38
(2,179)
(781.01)
(1,071)
(3,634)
810.08
Mean Deviation
N/A
1.78
1.77
4.15
5.71
2.25
5.11
4.12
4.29
3.88
Jensen Alpha
N/A
(0.31)
(0.12)
(0.1)
1.29
(0.12)
(1.12)
(0.75)
(0.29)
1.1
Total Risk Alpha
N/A
(0.65)
(0.49)
(1.03)
0.1038
(0.76)
(2.24)
(1.60)
(1.39)
(0.32)
Sortino Ratio
N/A
N/A
N/A
(0.02)
0.1801
N/A
N/A
N/A
N/A
0.2338
Downside Variance
N/A
N/A
N/A
26.04
52.09
N/A
N/A
N/A
N/A
18.46
Standard Deviation
N/A
2.49
2.54
6.57
8.36
3.7
7.81
6.33
7.46
9.19
Kurtosis
N/A
2.64
1.42
11.22
2.99
13.95
4.79
5.73
15.77
46.56
Potential Upside
N/A
3.79
4.84
8.96
16.34
4.05
9.27
8.0
6.33
5.6
Treynor Ratio
N/A
(0.58)
(0.52)
4.0E-4
1.35
0.3821
(1.07)
(0.47)
(0.34)
5.52
Maximum Drawdown
N/A
14.92
14.96
35.06
52.11
27.84
38.0
41.07
64.67
78.72
Variance
N/A
6.21
6.47
43.16
69.86
13.69
61.01
40.1
55.65
84.5
Market Risk Adjusted Performance
N/A
(0.57)
(0.51)
0.0104
1.36
0.3921
(1.06)
(0.46)
(0.33)
5.53
Risk Adjusted Performance
N/A
(0.07)
(0.02)
0.01
0.1399
(0.03)
(0.09)
(0.06)
(0.01)
0.1035
Skewness
N/A
0.8377
0.1592
2.02
0.4969
(2.77)
1.25
(0.91)
2.44
6.24
Semi Deviation
N/A
N/A
N/A
4.66
6.35
N/A
N/A
N/A
N/A
3.4
Information Ratio
N/A
(0.15)
(0.08)
(0.02)
0.1555
(0.08)
(0.14)
(0.11)
(0.05)
0.1093
Value At Risk
N/A
(4.58)
(4.48)
(6.94)
(6.25)
(3.53)
(10.28)
(10.00)
(8.10)
(6.33)
Expected Short fall
N/A
N/A
N/A
(5.96)
(6.70)
N/A
N/A
N/A
N/A
(4.53)
Downside Deviation
N/A
N/A
N/A
5.1
7.22
N/A
N/A
N/A
N/A
4.3
Semi Variance
N/A
N/A
N/A
21.69
40.27
N/A
N/A
N/A
N/A
11.55

Eiger Biopharmaceutica Competition Performance Charts

Five steps to successful analysis of Eiger Biopharmaceutica Competition

Eiger Biopharmaceutica's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Eiger Biopharmaceuticals in relation to its competition. Eiger Biopharmaceutica's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Eiger Biopharmaceutica in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Eiger Biopharmaceutica's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Eiger Biopharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Eiger Biopharmaceutica position

In addition to having Eiger Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Trading Thematic Idea Now

Trading
Trading Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Trading theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Trading Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Eiger Stock

If you are still planning to invest in Eiger Biopharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eiger Biopharmaceutica's history and understand the potential risks before investing.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
CEOs Directory
Screen CEOs from public companies around the world
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY